Beijing Tiantan Biological Products Toekomstige groei
Future criteriumcontroles 2/6
Beijing Tiantan Biological Products is forecast to grow earnings and revenue by 19.7% and 19.8% per annum respectively. EPS is expected to grow by 20.6% per annum. Return on equity is forecast to be 13.7% in 3 years.
Belangrijke informatie
19.7%
Groei van de winst
20.6%
Groei van de winst per aandeel
| Biotechs winstgroei | 44.8% |
| Inkomstengroei | 19.8% |
| Toekomstig rendement op eigen vermogen | 13.7% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 30 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Beijing Tiantan Biological Products Co., Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Oct 29
Beijing Tiantan Biological Products (SHSE:600161) Ticks All The Boxes When It Comes To Earnings Growth
Oct 27Calculating The Fair Value Of Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161)
Oct 08Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Shares May Have Run Too Fast Too Soon
Sep 19Does Beijing Tiantan Biological Products (SHSE:600161) Deserve A Spot On Your Watchlist?
Jul 23Is Beijing Tiantan Biological Products Co., Ltd. (SHSE:600161) Expensive For A Reason? A Look At Its Intrinsic Value
Jun 09Beijing Tiantan Biological Products Co., Ltd.'s (SHSE:600161) Price Is Out Of Tune With Earnings
May 22We Think Beijing Tiantan Biological Products (SHSE:600161) Can Stay On Top Of Its Debt
Mar 16Do Beijing Tiantan Biological Products' (SHSE:600161) Earnings Warrant Your Attention?
Mar 01Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 8,237 | 1,975 | 1,820 | 2,459 | 10 |
| 12/31/2025 | 7,131 | 1,648 | 1,589 | 2,510 | 9 |
| 12/31/2024 | 5,928 | 1,361 | 1,082 | 1,119 | 3 |
| 9/30/2024 | 5,232 | 1,274 | 270 | 1,351 | N/A |
| 6/30/2024 | 5,331 | 1,269 | 1,183 | 2,328 | N/A |
| 3/31/2024 | 5,110 | 1,165 | 1,087 | 2,242 | N/A |
| 12/31/2023 | 5,180 | 1,110 | 1,316 | 2,394 | N/A |
| 9/30/2023 | 5,371 | 1,167 | 1,254 | 2,515 | N/A |
| 6/30/2023 | 5,062 | 1,063 | 341 | 1,633 | N/A |
| 3/31/2023 | 4,848 | 1,018 | 250 | 1,539 | N/A |
| 12/31/2022 | 4,261 | 881 | -228 | 1,126 | N/A |
| 9/30/2022 | 4,207 | 803 | -195 | 1,097 | N/A |
| 6/30/2022 | 4,191 | 808 | -187 | 1,117 | N/A |
| 3/31/2022 | 3,970 | 733 | -351 | 918 | N/A |
| 12/31/2021 | 4,112 | 760 | -151 | 980 | N/A |
| 9/30/2021 | 3,628 | 700 | -241 | 728 | N/A |
| 6/30/2021 | 3,702 | 692 | -120 | 640 | N/A |
| 3/31/2021 | 3,535 | 659 | -71 | 571 | N/A |
| 12/31/2020 | 3,446 | 639 | 93 | 702 | N/A |
| 9/30/2020 | 3,398 | 641 | 306 | 755 | N/A |
| 6/30/2020 | 3,276 | 601 | 362 | 877 | N/A |
| 3/31/2020 | 3,334 | 611 | 184 | 741 | N/A |
| 12/31/2019 | 3,282 | 611 | 116 | 642 | N/A |
| 9/30/2019 | 3,394 | 580 | 282 | 788 | N/A |
| 6/30/2019 | 3,271 | 563 | 376 | 801 | N/A |
| 3/31/2019 | 3,083 | 531 | 729 | 1,028 | N/A |
| 12/31/2018 | 2,931 | 509 | 384 | 678 | N/A |
| 9/30/2018 | 2,929 | 568 | 538 | 767 | N/A |
| 6/30/2018 | 2,671 | 532 | N/A | 590 | N/A |
| 3/31/2018 | 2,485 | 1,228 | N/A | 186 | N/A |
| 12/31/2017 | 2,483 | 1,173 | N/A | 138 | N/A |
| 9/30/2017 | 2,362 | 1,077 | N/A | 301 | N/A |
| 6/30/2017 | 2,256 | 1,038 | N/A | 280 | N/A |
| 3/31/2017 | 2,330 | 313 | N/A | 344 | N/A |
| 12/31/2016 | 2,138 | 257 | N/A | 433 | N/A |
| 9/30/2016 | 1,756 | 151 | N/A | 251 | N/A |
| 6/30/2016 | 1,709 | 55 | N/A | 403 | N/A |
| 3/31/2016 | 1,624 | -3 | N/A | 471 | N/A |
| 12/31/2015 | 1,618 | 10 | N/A | 473 | N/A |
| 9/30/2015 | 1,545 | -88 | N/A | 384 | N/A |
| 6/30/2015 | 1,567 | -46 | N/A | 382 | N/A |
| 3/31/2015 | 1,723 | 46 | N/A | 560 | N/A |
| 12/31/2014 | 1,827 | 128 | N/A | 478 | N/A |
| 9/30/2014 | 2,026 | 291 | N/A | 748 | N/A |
| 6/30/2014 | 2,018 | 377 | N/A | 705 | N/A |
| 3/31/2014 | 1,905 | 371 | N/A | 490 | N/A |
| 12/31/2013 | 1,837 | 372 | N/A | 566 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: 600161's forecast earnings growth (19.7% per year) is above the savings rate (2.9%).
Winst versus markt: 600161's earnings (19.7% per year) are forecast to grow slower than the CN market (25.8% per year).
Hoge groeiwinsten: 600161's earnings are forecast to grow, but not significantly.
Omzet versus markt: 600161's revenue (19.8% per year) is forecast to grow faster than the CN market (14% per year).
Hoge groei-inkomsten: 600161's revenue (19.8% per year) is forecast to grow slower than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: 600161's Return on Equity is forecast to be low in 3 years time (13.7%).